Vitality Watch

Dossier pubmed review 17-jul-2026
Narrative review or expert overview without new data

Is Urolithin A(UA) a pharmacologically credible neuro-nutraceutical? A critical review of mechanisms, brain exposure, and evidence gaps in Alzheimer’s and Parkinson’s disease.

Key claim: Urolithin A has convergent preclinical support for restoring PINK1/Parkin mitophagy and dampening neuroinflammation in AD/PD models, plus human evidence for safety and muscle benefits, but remains an investigational neuro-nutraceutical with no completed cognitive or disease-modifying trials.

Abstract

Urolithin A(UA) is a gut microbiota-derived metabolite of dietary ellagitannins and ellagic acid, generated by specific gut bacterial species and absent from food in free form. Preclinical evidence indicates that UA restores PINK1/Parkin-mediated mitophagy, attenuates NF-κB, NLRP3 inflammasome and cGAS-STING-driven neuroinflammation, and preserves synaptic and cognitive function across rodent and cell-culture models of Alzheimer’s disease, Parkinson’s disease, and age-related cognitive decline. However, circulating UA in humans exists predominantly as phase II glucuronide and sulfate conjugates rather than free aglycone, and human clinical evidence to date establishes UA’s safety, favorable pharmacokinetics, mitochondrial target engagement, and benefits to muscle strength and physical function in middle-aged and older adults, with no completed trial yet evaluating cognitive or neurodegenerative disease-modifying outcomes. This review critically examines whether UA’s neuroprotective mechanisms are pathway-specific and supported by convergent preclinical and human data, while explicitly separating mechanistic plausibility from demonstrated clinical efficacy.UA therefore represents a promising but still investigational neuro-nutraceutical candidate, with a mechanistic foundation strong enough to justify dedicated, CNS-endpoint-focused clinical trials as the next logical step toward establishing its neuroprotective potential in humans.

Why this matters

Urolithin A is one of the clearest cases where a mechanism-area narrative (PINK1/Parkin mitophagy restoration, dampened cGAS–STING/NLRP3 microglial signaling) has been packaged into a commercially advanced neuro-nutraceutical pitch while the human evidence base remains confined to safety and skeletal-muscle endpoints. This critical review formalizes the gap between convergent preclinical neuroprotection and absent CNS clinical trials, and highlights microbiota producer-status as an under-addressed stratifier for any future neuro-outcome study.

Source

Link

Briefing card

Is Urolithin A(UA) a pharmacologically credible neuro-nutraceutical? A critical review of mechanisms, brain exposure, and evidence gaps in Alzheimer's and Parkinson's disease.
Stage: review · pubmed · 17-jul-2026

If you take urolithin A hoping for brain or Alzheimer's/Parkinson's benefit, no completed human trial has tested those endpoints — current support is preclinical and mechanistic only.

Urolithin A has convergent preclinical support for restoring PINK1/Parkin mitophagy and dampening neuroinflammation in AD/PD models, plus human evidence for safety and muscle benefits, but remains an investigational neuro-nutraceutical with no completed cognitive or disease-modifying trials.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1016/j.neuint.2026.106224

build build 880 · 2bcef25 · 2026-11-18